Is a complete RNAZ research report available?

No complete published report is available for TransCode Therapeutics, Inc. (RNAZ) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

TransCode Therapeutics, Inc. (RNAZ)

NASDAQ: RNAZ · USD

$1.57

-0.06 (-3.7%)· Recorded snapshot

Market cap	26.6M
Net income (ttm)	-46.3M
EPS (ttm)	-$51.1
Shares out	16.9M
Volume	29,550.101
Beta	1.27

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -46.3M
EPS (ttm): -$51.1
Market cap: 26.6M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	احتفاظ

Metric	Value
Amount currency	USD
CIK code	0001829635
Company name	TransCode Therapeutics, Inc.
Country	United States
Country code	US
CUSIP number	89357L501
Earnings date	2026-08-14
Earnings time	amc
Employees	12
Employees change	5
Employees growth	71.43%
Enterprise value	$18.9M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2016
Industry	Biotechnology
IPO date	2021-07-09
Is primary listing	Yes
Is SPAC	No
ISIN number	US89357L5012
Last 10-K release date	2026-04-15
Last earnings date	2026-08-14
Last refreshed	2026-11-04
Last stock split date	2025-05-15
Last stock split type	Reverse
Market cap	$26.6M
Market cap category	Nano-Cap
Next earnings date	2027-02-13
Options	No
Price	$1.57
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-11-03
Symbol	RNAZ
U.S. state	Massachusetts
Website	https://www.transcodetherapeutics.com

Metric

Value

Amount currency

USD

CIK code

0001829635

Company name

TransCode Therapeutics, Inc.

Country

United States

Country code

CUSIP number

89357L501

Earnings date

2026-08-14

Earnings time

amc

Employees

Employees change

Employees growth

71.43%

Enterprise value

$18.9M

Exchange

NASDAQ

Financial currency

USD

Financial report date

2026-06-30

First seen

2026-05-09

Fiscal year end

December

Founded

2016

Industry

Biotechnology

IPO date

2021-07-09

Is primary listing

Yes

Is SPAC

ISIN number

US89357L5012

Last 10-K release date

2026-04-15

Last earnings date

2026-08-14

Last refreshed

2026-11-04

Last stock split date

2025-05-15

Last stock split type

Reverse

Market cap

$26.6M

Market cap category

Nano-Cap

Next earnings date

2027-02-13

Options

Price

$1.57

Price currency

USD

Sector

Healthcare

SIC code

2834

Stock price date

2026-11-03

Symbol

RNAZ

U.S. state

Massachusetts

Website

https://www.transcodetherapeutics.com

Metric	Value
Earnings yield	-3,253.29%
FCF / EV yield	-119.96%
FCF yield	-85.07%
P/B ratio	0.19x
Sector forward P/E	23.32x
Sector P/E	49.47x

Metric

Value

Earnings yield

-3,253.29%

FCF / EV yield

-119.96%

FCF yield

-85.07%

P/B ratio

0.19x

Sector forward P/E

23.32x

Sector P/E

49.47x

Metric	Value
Profit per employee	$-3.9M
ROA	-19.9%
ROA (5Y)	-93.96%
ROCE	-17.42%
ROE	-59.28%
ROIC	-21.84%

Metric

Value

Profit per employee

$-3.9M

ROA

-19.9%

ROA (5Y)

-93.96%

ROCE

-17.42%

ROE

-59.28%

ROIC

-21.84%

Metric	Value
EPS growth years	3
Net income growth years	0
Revenue growth years	0

Metric

Value

EPS growth years

Net income growth years

Revenue growth years

Metric	Value
Capital expenditures	$-6,660
Depreciation and amortization	$97,434
EBIT	$-25.4M
EBITDA	$-25.3M
EPS	$-51.08
FCF per share	$-1.34
Financing cash flow	$23.6M
Free cash flow	$-22.6M
Free cash flow minus SBC	$-22.8M
Income taxes	$457,677
Investing cash flow	$-4,436
Net borrowing	$950,000
Net cash flow	$1M
Net income	$-46.3M
Operating cash flow minus SBC	$-22.8M
Operating income	$-25.4M
Stock-based compensation	$196,189

Metric

Value

Capital expenditures

$-6,660

Depreciation and amortization

$97,434

EBIT

$-25.4M

EBITDA

$-25.3M

EPS

$-51.08

FCF per share

$-1.34

Financing cash flow

$23.6M

Free cash flow

$-22.6M

Free cash flow minus SBC

$-22.8M

Income taxes

$457,677

Investing cash flow

$-4,436

Net borrowing

$950,000

Net cash flow

$1M

Net income

$-46.3M

Operating cash flow minus SBC

$-22.8M

Operating income

$-25.4M

Stock-based compensation

$196,189

Metric	Value
Book value per share	$-27.38
Debt / equity	0
Goodwill	$25.7M
Interest coverage	-3,900.25
Long-term assets	$140.4M
Long-term liabilities	$7.3M
Net cash (debt)	$7.7M
Net cash / market cap	29.08%
Net cash growth	4.83%
Net debt / equity	-0.06
Piotroski F-Score	1
Property, plant and equipment	$322,809
Shareholders' equity	$138.4M
Tangible book value	$-167.7M
Tangible book value per share	$-165.82
Total assets	$151M
Total cash	$8.4M
Total debt	$652,411
Total liabilities	$12.7M
WACC	10.97%

Metric

Value

Book value per share

$-27.38

Debt / equity

Goodwill

$25.7M

Interest coverage

-3,900.25

Long-term assets

$140.4M

Long-term liabilities

$7.3M

Net cash (debt)

$7.7M

Net cash / market cap

29.08%

Net cash growth

4.83%

Net debt / equity

-0.06

Piotroski F-Score

Property, plant and equipment

$322,809

Shareholders' equity

$138.4M

Tangible book value

$-167.7M

Tangible book value per share

$-165.82

Total assets

$151M

Total cash

$8.4M

Total debt

$652,411

Total liabilities

$12.7M

WACC

10.97%

Metric	Value
Current assets	$10.6M
Current liabilities	$5.4M
Current ratio	1.97
Net working capital	$-2.5M
Quick ratio	1.55
Working capital	$5.2M

Metric

Value

Current assets

$10.6M

Current liabilities

$5.4M

Current ratio

1.97

Net working capital

$-2.5M

Quick ratio

1.55

Working capital

$5.2M

Metric	Value
Buyback yield / dilution	-246.69%
Dividend yield	0%
Shareholder yield	-246.69%

Metric

Value

Buyback yield / dilution

-246.69%

Dividend yield

Shareholder yield

-246.69%

Metric	Value
150-day SMA	$4.90
1D price change	-3.68%
1W price change	-5.99%
1W total return	-5.99%
1Y price change	-85.98%
1Y return CAGR	-86%
1Y total return	-85.98%
20-day SMA	$1.70
200-day SMA	$6.08
3M price change	-65.57%
3M total return	-65.57%
3Y price change	-99.99%
3Y return CAGR	-95.11%
3Y total return	-99.99%
50-day SMA	$1.79
50-day SMA vs 200-day SMA	50under200
52-week high	$12.60
52-week high date	2026-01-26
52-week low	$1.50
52-week low date	2026-11-03
5Y price change	-100%
5Y return CAGR	-94.21%
5Y total return	-100%
6M price change	-79.95%
6M total return	-79.95%
All-time high	$5,174,452.99
All-time high date	2021-07-09
All-time low	$1.50
All-time low date	2026-11-03
Average true range (ATR)	$0.17
Average volume	32.3K
Beta (1Y)	1.01
Beta (2Y)	2.63
Beta (5Y)	1.27
Change from 52-week high	-87.54%
Change from 52-week low	4.67%
Change from all-time high	-100%
Change from all-time low	4.67%
Change from open	-1.88%
Day's gap	-1.84%
Dollar volume	$46,394
High price	$1.65
Low price	$1.50
Monthly RSI	22.65
Open price	$1.60
Position in 52-week range	46.67%
Premarket change	1.27%
Premarket close	$1.57
Premarket price	$1.59
Previous close	$1.63
Price vs 150-day SMA	-67.96%
Price vs 20-day SMA	-7.86%
Price vs 200-day SMA	-74.18%
Price vs 50-day SMA	-12.14%
Relative volume	0.91
Return from IPO open	-100%
Return from IPO price	-60.75%
RSI	38.09
Sharpe ratio	-1.7
Sharpe ratio (3Y)	-1.08
Sharpe ratio (5Y)	-0.6
Sortino ratio	-2.45
Sortino ratio (3Y)	-1.5
Sortino ratio (5Y)	-1.11
Volume	29.6K
Weekly RSI	29.15
YTD price change	-77.01%
YTD total return	-77.01%

Metric

Value

150-day SMA

$4.90

1D price change

-3.68%

1W price change

-5.99%

1W total return

-5.99%

1Y price change

-85.98%

1Y return CAGR

-86%

1Y total return

-85.98%

20-day SMA

$1.70

200-day SMA

$6.08

3M price change

-65.57%

3M total return

-65.57%

3Y price change

-99.99%

3Y return CAGR

-95.11%

3Y total return

-99.99%

50-day SMA

$1.79

50-day SMA vs 200-day SMA

50under200

52-week high

$12.60

52-week high date

2026-01-26

52-week low

$1.50

52-week low date

2026-11-03

5Y price change

-100%

5Y return CAGR

-94.21%

5Y total return

-100%

6M price change

-79.95%

6M total return

-79.95%

All-time high

$5,174,452.99

All-time high date

2021-07-09

All-time low

$1.50

All-time low date

2026-11-03

Average true range (ATR)

$0.17

Average volume

32.3K

Beta (1Y)

1.01

Beta (2Y)

2.63

Beta (5Y)

1.27

Change from 52-week high

-87.54%

Change from 52-week low

4.67%

Change from all-time high

-100%

Change from all-time low

4.67%

Change from open

-1.88%

Day's gap

-1.84%

Dollar volume

$46,394

High price

$1.65

Low price

$1.50

Monthly RSI

22.65

Open price

$1.60

Position in 52-week range

46.67%

Premarket change

1.27%

Premarket close

$1.57

Premarket price

$1.59

Previous close

$1.63

Price vs 150-day SMA

-67.96%

Price vs 20-day SMA

-7.86%

Price vs 200-day SMA

-74.18%

Price vs 50-day SMA

-12.14%

Relative volume

0.91

Return from IPO open

-100%

Return from IPO price

-60.75%

RSI

38.09

Sharpe ratio

-1.7

Sharpe ratio (3Y)

-1.08

Sharpe ratio (5Y)

-0.6

Sortino ratio

-2.45

Sortino ratio (3Y)

-1.5

Sortino ratio (5Y)

-1.11

Volume

29.6K

Weekly RSI

29.15

YTD price change

-77.01%

YTD total return

-77.01%

Metric	Value
Float	2.2M
Float percentage	12.72%
Shares change (QoQ)	4.39%
Shares change (YoY)	246.69%
Shares held by insiders	2.03%
Shares held by institutions	0.52%
Shares outstanding	16.9M
Short % of float	2.55%
Short % of shares	0.32%
Short ratio	1 days

Metric

Value

Float

2.2M

Float percentage

12.72%

Shares change (QoQ)

4.39%

Shares change (YoY)

246.69%

Shares held by insiders

2.03%

Shares held by institutions

0.52%

Shares outstanding

16.9M

Short % of float

2.55%

Short % of shares

0.32%

Short ratio

1 days

TransCode Therapeutics, Inc. (RNAZ)

Price

Financial snapshot

Fair-value bridge

Latest news · RNAZ

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All RNAZ indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on RNAZ

Frequently asked questions